Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells

Kathleen A. Elliott, Natalia A. Osna, Margaret A. Scofield, Manzoor M. Khan

Research output: Contribution to journalArticle

Abstract

Histamine affects the balance of T helper type 1 (Th1) and T helper type 2 (Th2) cytokines by shifting cytokine production from a Th1 to a Th2 pattern. Interleukin-13 (IL-13) is an important autacoid mediator that has been implicated in the development of allergic disease. This study was designed to investigate the mechanisms of regulation of IL-13 by histamine in Th2 cells. D10.G4.1 cells, a murine Th2 cell line, were treated with histamine (10-8-10-4 M) and then activated with PMA (phorbol 12 myristate 13-acetate) plus ionomycin or αCD3. Levels of IL-13 production were then measured by enzyme-linked immunosorbent assay (ELISA) and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Cells were pretreated with histamine receptor antagonists pyrilamine, ranitidine, cimetidine and thioperamide to determine the involvement of histamine receptors. Cells were also pretreated with protein kinase A (PKA) inhibitors N-[2-(methylaminoethyl)]-5-isoquinoline-sulfonamide (H-8) and Rp-diastereomer of adenosine cyclic 3′5′-phosphorothionate (Rp-cAMPS), and Janus kinase-signal transducer and activator of transcription (Jak-STAT) inhibitor tyrphostin AG490 prior to the addition of histamine. H-8 is an inhibitor of the catalytic subunit of PKA while Rp-cAMPS is an inhibitor of the regulatory subunit of PKA. Tyrphostin is an inhibitor of Jak2, Jak3, STAT1, STAT3 and STAT5. Finally, cells were pretreated with IL-12, a monokine known to repress STAT6 DNA binding. We found that histamine dose-dependently enhanced IL-13 secretion and mRNA levels in Th2 cells via H1 and H2 receptors. Pretreatment of cells with H-8, Rp-cAMPS and tyrphostin prevented histamine-induced secretion and transcription of IL-13. Likewise, pretreatment of Th2 cells with IL-12 also reversed histamine's effects on IL-13 secretion from stimulatory to inhibitory. These observations suggest a role for PKA and the Jak-STAT pathway in histamine-mediated elevation of IL-13 secretion and transcription.

Original languageEnglish (US)
Pages (from-to)1923-1937
Number of pages15
JournalInternational Immunopharmacology
Volume1
Issue number11
DOIs
StatePublished - Sep 22 2001

Fingerprint

Genetic Transcription
Janus Kinases
Th2 Cells
Interleukin-13
Histamine Antagonists
Enzyme Inhibitors
Interleukin-12
Cyclic AMP-Dependent Protein Kinases
Cyclic AMP
Histamine
Culture Media
Up-Regulation
Spleen
Clone Cells
Cell Line
Messenger RNA
Tyrphostins
Histamine Receptors
thioperamide
Transducers

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells. / Elliott, Kathleen A.; Osna, Natalia A.; Scofield, Margaret A.; Khan, Manzoor M.

In: International Immunopharmacology, Vol. 1, No. 11, 22.09.2001, p. 1923-1937.

Research output: Contribution to journalArticle

Elliott, Kathleen A. ; Osna, Natalia A. ; Scofield, Margaret A. ; Khan, Manzoor M. / Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells. In: International Immunopharmacology. 2001 ; Vol. 1, No. 11. pp. 1923-1937.
@article{79429572d3534527bb78b46c8f414e38,
title = "Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells",
abstract = "Histamine affects the balance of T helper type 1 (Th1) and T helper type 2 (Th2) cytokines by shifting cytokine production from a Th1 to a Th2 pattern. Interleukin-13 (IL-13) is an important autacoid mediator that has been implicated in the development of allergic disease. This study was designed to investigate the mechanisms of regulation of IL-13 by histamine in Th2 cells. D10.G4.1 cells, a murine Th2 cell line, were treated with histamine (10-8-10-4 M) and then activated with PMA (phorbol 12 myristate 13-acetate) plus ionomycin or αCD3. Levels of IL-13 production were then measured by enzyme-linked immunosorbent assay (ELISA) and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Cells were pretreated with histamine receptor antagonists pyrilamine, ranitidine, cimetidine and thioperamide to determine the involvement of histamine receptors. Cells were also pretreated with protein kinase A (PKA) inhibitors N-[2-(methylaminoethyl)]-5-isoquinoline-sulfonamide (H-8) and Rp-diastereomer of adenosine cyclic 3′5′-phosphorothionate (Rp-cAMPS), and Janus kinase-signal transducer and activator of transcription (Jak-STAT) inhibitor tyrphostin AG490 prior to the addition of histamine. H-8 is an inhibitor of the catalytic subunit of PKA while Rp-cAMPS is an inhibitor of the regulatory subunit of PKA. Tyrphostin is an inhibitor of Jak2, Jak3, STAT1, STAT3 and STAT5. Finally, cells were pretreated with IL-12, a monokine known to repress STAT6 DNA binding. We found that histamine dose-dependently enhanced IL-13 secretion and mRNA levels in Th2 cells via H1 and H2 receptors. Pretreatment of cells with H-8, Rp-cAMPS and tyrphostin prevented histamine-induced secretion and transcription of IL-13. Likewise, pretreatment of Th2 cells with IL-12 also reversed histamine's effects on IL-13 secretion from stimulatory to inhibitory. These observations suggest a role for PKA and the Jak-STAT pathway in histamine-mediated elevation of IL-13 secretion and transcription.",
author = "Elliott, {Kathleen A.} and Osna, {Natalia A.} and Scofield, {Margaret A.} and Khan, {Manzoor M.}",
year = "2001",
month = "9",
day = "22",
doi = "10.1016/S1567-5769(01)00117-5",
language = "English (US)",
volume = "1",
pages = "1923--1937",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells

AU - Elliott, Kathleen A.

AU - Osna, Natalia A.

AU - Scofield, Margaret A.

AU - Khan, Manzoor M.

PY - 2001/9/22

Y1 - 2001/9/22

N2 - Histamine affects the balance of T helper type 1 (Th1) and T helper type 2 (Th2) cytokines by shifting cytokine production from a Th1 to a Th2 pattern. Interleukin-13 (IL-13) is an important autacoid mediator that has been implicated in the development of allergic disease. This study was designed to investigate the mechanisms of regulation of IL-13 by histamine in Th2 cells. D10.G4.1 cells, a murine Th2 cell line, were treated with histamine (10-8-10-4 M) and then activated with PMA (phorbol 12 myristate 13-acetate) plus ionomycin or αCD3. Levels of IL-13 production were then measured by enzyme-linked immunosorbent assay (ELISA) and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Cells were pretreated with histamine receptor antagonists pyrilamine, ranitidine, cimetidine and thioperamide to determine the involvement of histamine receptors. Cells were also pretreated with protein kinase A (PKA) inhibitors N-[2-(methylaminoethyl)]-5-isoquinoline-sulfonamide (H-8) and Rp-diastereomer of adenosine cyclic 3′5′-phosphorothionate (Rp-cAMPS), and Janus kinase-signal transducer and activator of transcription (Jak-STAT) inhibitor tyrphostin AG490 prior to the addition of histamine. H-8 is an inhibitor of the catalytic subunit of PKA while Rp-cAMPS is an inhibitor of the regulatory subunit of PKA. Tyrphostin is an inhibitor of Jak2, Jak3, STAT1, STAT3 and STAT5. Finally, cells were pretreated with IL-12, a monokine known to repress STAT6 DNA binding. We found that histamine dose-dependently enhanced IL-13 secretion and mRNA levels in Th2 cells via H1 and H2 receptors. Pretreatment of cells with H-8, Rp-cAMPS and tyrphostin prevented histamine-induced secretion and transcription of IL-13. Likewise, pretreatment of Th2 cells with IL-12 also reversed histamine's effects on IL-13 secretion from stimulatory to inhibitory. These observations suggest a role for PKA and the Jak-STAT pathway in histamine-mediated elevation of IL-13 secretion and transcription.

AB - Histamine affects the balance of T helper type 1 (Th1) and T helper type 2 (Th2) cytokines by shifting cytokine production from a Th1 to a Th2 pattern. Interleukin-13 (IL-13) is an important autacoid mediator that has been implicated in the development of allergic disease. This study was designed to investigate the mechanisms of regulation of IL-13 by histamine in Th2 cells. D10.G4.1 cells, a murine Th2 cell line, were treated with histamine (10-8-10-4 M) and then activated with PMA (phorbol 12 myristate 13-acetate) plus ionomycin or αCD3. Levels of IL-13 production were then measured by enzyme-linked immunosorbent assay (ELISA) and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Cells were pretreated with histamine receptor antagonists pyrilamine, ranitidine, cimetidine and thioperamide to determine the involvement of histamine receptors. Cells were also pretreated with protein kinase A (PKA) inhibitors N-[2-(methylaminoethyl)]-5-isoquinoline-sulfonamide (H-8) and Rp-diastereomer of adenosine cyclic 3′5′-phosphorothionate (Rp-cAMPS), and Janus kinase-signal transducer and activator of transcription (Jak-STAT) inhibitor tyrphostin AG490 prior to the addition of histamine. H-8 is an inhibitor of the catalytic subunit of PKA while Rp-cAMPS is an inhibitor of the regulatory subunit of PKA. Tyrphostin is an inhibitor of Jak2, Jak3, STAT1, STAT3 and STAT5. Finally, cells were pretreated with IL-12, a monokine known to repress STAT6 DNA binding. We found that histamine dose-dependently enhanced IL-13 secretion and mRNA levels in Th2 cells via H1 and H2 receptors. Pretreatment of cells with H-8, Rp-cAMPS and tyrphostin prevented histamine-induced secretion and transcription of IL-13. Likewise, pretreatment of Th2 cells with IL-12 also reversed histamine's effects on IL-13 secretion from stimulatory to inhibitory. These observations suggest a role for PKA and the Jak-STAT pathway in histamine-mediated elevation of IL-13 secretion and transcription.

UR - http://www.scopus.com/inward/record.url?scp=0034839238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034839238&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(01)00117-5

DO - 10.1016/S1567-5769(01)00117-5

M3 - Article

C2 - 11606024

AN - SCOPUS:0034839238

VL - 1

SP - 1923

EP - 1937

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 11

ER -